当地的生物仿制药政策能否优化自由资源的利用——意大利的经验

IF 0.3 Q4 PHARMACOLOGY & PHARMACY

GaBI Journal-Generics and Biosimilars Initiative Journal Pub Date : 2020-10-06 DOI:10.5639/GABIJ.2020.0904.029

B. Godman, E. Allocati, Evelien Moorkens, H. Kwon

引用次数: 9

摘要

越来越需要开生物仿制药以资助新药和增加药物量。Bertolani和Jommi记录了在意大利地区引进的成功措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Can local policies on biosimilars optimize the use of freed resources – experiences from Italy

There is an increasing need to prescribe biosimilars to fund new medicines and increasing medicine volumes. Bertolani and Jommi document successful measures introduced regionally in Italy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

GaBI Journal-Generics and Biosimilars Initiative Journal PHARMACOLOGY & PHARMACY-

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The scope of GaBI Journal is broad and of interest and relevance to professionals active in clinical practice, pharmaceutical science and policy. Materials published in GaBI Journal include high quality research reports, literature reviews and case studies, all of which are peer reviewed. Manuscripts on all aspects of generic and biosimilar medicines, covering areas in clinical, fundamental, technical, manufacturing, bi-processing, economic and social aspects of pharmaceuticals and therapeutics are welcome. In addition, high quality work submitted in other formats, for example, scientific and evidence-based commentaries, may also be considered. In all cases, the emphasis is on quality, originality and knowledge contribution to those involved in health care. All manuscripts submitted to GaBI Journal are subject to a rigorous peer review process. GaBI Journal plans to be indexed in PubMed within two years, and that indexing will be retrospective. GaBI Journal is published quarterly from 2012. All articles are published in English.